CIK 0001889109 · Large accelerated filer
BELITE BIO, INC
Sign in to watch- Ticker
- BLTE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- other
- Phone
- 858-246-6240
- Business address
- 12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA, 92130
- Former names
- BELITE BIO, INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $31,968,735
- in 3 filings, $32.0M under 10b5-1 plans
Net −$31,968,735. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-09 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 | −1,909 | $182.58 | $349K | 94,091 |
| 2026-04-09 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 | −291 | $183.08 | $53K | 93,800 |
| 2026-03-31 | Chen Wan-Shan Director | Grant or award · Stock Option (right to buy) | +13,796 | 13,796 | ||
| 2026-03-31 | Chuang Hao-Yuan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +144,868 | 289,736 | ||
| 2026-03-31 | MATA NATHAN L. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +144,868 | 267,934 | ||
| 2026-03-31 | Lin Yu-Hsin Chief Executive Officer | Grant or award · Stock Option (right to buy) | +206,954 | 413,908 |
Page 10 of 10 · 186 trades